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Plasma levels and urinary excretion of diphenhydramine were measured after administration of 
three single 50-mg doses of diphenhydramine hydroehloride to two healthy male volunteers as an 
intravenous infusion, an oral solution, and a commercially available capsule. A large first-pass 
effect was evident from the data, with about 50% of the drug being metabolized by the liver before 
it reached the general circulation. The drug in solution given orally appeared to be fully available 
to the hepatoportal system, and the availability of diphenhydramine from the capsule was about 
83 ~ relative to the solution in one subject and 100 ~ in the other subject. Cumulative amounts of 
unchanged diphenhydramine excreted in the urine were less than 4 o/s of the administered dose. 
Both sut)]ects went to sleep at the end of the 1-hr int~'avenous injusion, but were only drowsyJollowing 
the oral treatments. 
KEY WORDS: diphenhydramine: intravenous infusion: oral administration: first-pass effect: 
bioavailability. 
I N T R O D U C T I O N  
D i p h e n h y d r a m i n e  hydroch lor ide ,  2 - (d ipheny lme thoxy) -N ,N-d ime thy l -  
e thy lamine  hydroch lo r ide ,  is an effective an t ih i s t amin ic  agent  possessing 
ant ichol inergic ,  ant i tussive,  ant iemet ic ,  and  sedat ive p roper t i e s  (1). A l though  
the d rug  has  been used cl inical ly for m a n y  years,  relat ively l i t t le  in fo rmat ion  
This study was performed pursuant to Contract No. FDA 69-22 with Public Health Service, 
Food and Drug Administration, Department of Health, Education, and Welfare, and was 
supported in part by Public Health Service Grant 5-P11-GM15559. 
~Present address: Merck Sharp and Dohme Research Laboratories, West Point, Pennsylvania 
19486. 
2College of Pharmacy and Upjohn Center for Clinical Pharmacology, The University of 
Michigan, Ann Arbor, Michigan 48104. 
3Address reprint requests to Dr. John G. Wagner, Upjohn Center for Clinical Pharmacology, 
The University of Michigan, Ann Arbor, Michigan 48104. 
159 
9 1975 Plenum Publishing Corporation, 227 West 17th Street, New York, N.Y. 1001 I. No part of this publication 
may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, 
photocopying, microfilming, recording, or otherwise, without written permission of the publisher, 
160 Albert, Hallmark, Sakmar, Weidler, and Wagner 
is available on its absorption, distribution, and elimination in man. Hald (2) 
found that 3 }~ of a therapeutic dose (50 or 100 mg) of the drug was excreted 
unchanged in human urine. Glazko et al. (3) administered 50-mg oral doses 
of diphenhydramine (as its salicylate and hydrochloride salts) twice and 
four times daily to five subjects for 5 consecutive days. Average peak plasma 
levels were 84 +_ 30 and 160 +__ 25 ng/ml, respectively, for the two dose 
levels (after accumulation had occurred during days 1-5). In addition, an 
apparent plasma half-life of about 18 hr was reported. 
The present pilot study was undertaken to elucidate the pharmaco- 
kinetic parameters of diphenhydramine in man after administration of the 
drug as an intravenous infusion, an oral solution, and a commercially 




Two healthy adult male volunteers both 27 years of age and weighing 
76 and 95 kg, with normal vital signs and laboratory screening values, were 
selected for the study. Each subject received three single 50-mg doses of 
diphenhydramine hydrochloride as an intravenous infusion, an oral solution, 
and a commercially available capsule according to the dosage schedules 
shown in Table I. Treatments were separated by a 2-week period. The subjects 
fasted from 10 hr prior to dosing until 4 hr after administration of the drug. 
In order to assure hemodynamics similar to that when the drug was given 
orally, subjects were required to stand periodically during the infusion. 
Twenty-milliliter blood samples were collected in citrated Vacutainers 
just prior to dosing and at the times indicated in Table II. The plasma was 
separated, frozen, and kept in a frozen state until just prior to assay. Urine 
specimens were collected in plastic bottles containing 1 ml of toluene for the 
following time intervals after administration: 0-6, 6-24, and 24-48 hr. The 
volumes were recorded, the urine was acidified with concentrated hydro- 
chloric acid (to back-extract any diphenhydramine that may have partitioned 
into the toluene layer), and an aliquot was frozen until just prior to assay. 
Analytical Method 
Plasma and urine specimens were assayed for diphenhydramine by a 
GLC procedure shown to be specific for unchanged drug (4). In addition, the 
contents of the intravenous infusion and oral solution dosage forms were 
assayed for exact drug content. 
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Table !. Dosage Schedules and Treatments 
Subject given treatment 
A" B b C c 
(intravenous (oral 
Phase infusion) solution) (capsule) 
i - -  1 2 
II - -  2 l 
Il l  1,2 - -  - -  
qntravenous infusion: The contents of three 
1-ml Benadryl ampules, 50mg/ml (Parke, 
Davis and Company, Detroit), were diluted 
aseptically with 717 ml of 5 ~o sterile dextrose. 
A 240-ml portion was infused over 1 hr at a 
rate of 4 rot/rain using a precalibrated infusion 
pump. 
bOral solution : The contents of one Benadryl 
Kapseal, 50 mg, dissolved in a mixture of 90 
ml of deionized water and 30 ml of Coca-Cola 
syrup, were swallowed; the container was 
rinsed with 120 ml of deionized water and the 
rinsings were swallowed. 
cCapsule: One Benadryl Kapseal, 50 mg, was 
swallowed intact with 240ml of deionized 
water. 
D e t e r m i n a t i o n  o f  W h o l e  B l o o d / P l a s m a  D i s t r i b u t i o n  R a t i o  
Two-mi l l i l i t e r  po r t ions  of  c i t ra ted  drug-f ree  whole  b l o o d  f rom each 
subject  were incuba ted  with t r i t ium- labe led  d i p h e n h y d r a m i n e  hyd roc h lo r i de  
(specific ac t iv i ty  13.4#Ci /mg,  suppl ied  by Parke ,  Davis  and  C o m p a n y )  4 
for 30 ra in  at  37~ using an aqueous  s tock  solut ion,  11.3#g/mE F ina l  
concen t ra t ions  of  d i p h e n h y d r a m i n e  h y d r o c h l o r i d e  were 113 and  904 ng/ml. 
After incuba t ion ,  the  p l a sma  was separa ted  by centr i fuging at  2 0 0 0 r p m  
for 20 rain. The samples  were ana lyzed  for r ad ioac t iv i ty  by add ing  100/d 
of each to  15 rnl Unoge l  (Schwarz /Mann  Co.) and  coun t ing  for 10 rain in a 
sc in t i l la t ion coun te r  ( P a c k a r d  T r i - C a r b  l iquid  sc in t i l la t ion  spectrometer) .  
The whole  b l o o d / p l a s m a  ra t io  was ca lcu la ted  by c o m p a r i n g  the rad ioac t iv i ty  
of  whole  b lood  samples  to s imilar ly  t rea ted  p l a s m a  s t anda rds  con ta in ing  
113 and  904 ng/ml  of  t r i t ia ted  d i p h e n h y d r a m i n e  hydroch lor ide .  
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Determination of Plasma Protein Binding 
Two-milliliter portions of drug-free plasma from each Subject were 
incubated for 30 rain at 37~ with tritium-labeled diphenhydramine hydro- 
chloride using an aqueous stock solution. 11.3 pg/ml. Final concentrations 
were 113 and 1130 ng/ml. 
Ultrafiltration of the plasma samples was performed at 37~ in mem- 
brane cones (Centriflo CF-50 membrane tiltrafilter, Amicon Corp.) which 
were soaked in deionized water for at least 1 hr before Use. After removal of 
residual water by centrifugation at 1000g for 5 rain, 1.9 ml of plasma was 
pipetted into the cone. then centrifuged at 800g for 30 rain. At the end of the 
centrifugation, 100-/d aliquots of ultrafiltrate were removed for scintillation 
counting as described above. A 100-pl portion of plasma was analyzed for 
radioactivity prior to centrifugation, The unbound fraction was calculated 
as the quotient of the radioactivity in the uitrafiltrate and in the plasma 
before ultrafiltration. 
Data Analysis 
The total area under the plasma concentration time curve from zero to 
infinity was estimated for each of the six sets of data by two different methods. 
One method involved fitting of the concentration time data to a poly- 
exponential equation using the program AUTOAN (5) and an I B M  360/67 
digital computer. The polyexponential equation was then integrated to 
obtain the area. The program AUTOAN interpolates one plasma concen- 
tration-time point between each pair of real points by spline and Akima 
methods (6). It then calculates every possible polyexponential equation from 
one to five exponential terms which could describe the data and provides 
the coefficients and exponents for the optimum number of terms. The 
criterion used is a moving scale percentage improvement in the sum of 
squared deviations depending on the value of r 2 (defined in footnote b to 
Table III). The other method involved estimating the area from 0 to 24 hr 
by means Of the trapezoidal rule. then estimating the area from 24 hr to 
infinity by dividing the observed plasma concentration at 24hr  by the 
/~ Value estimated from the i2- and 24-hr plasma concentrations observed 
following intravenous infusion of the drug. 
RESULTS AND DISCUSSION 
Table II summarizes both the plasma concentration and urinary ex- 
cretion data for subjects 1 and 2 following the three treatments. A first-pass 
effect 5 was evident from the data, which showed that the area under the oral 
5The apparent plasma clearances, estimated directly from the intravenous infusion data in 
Tabte II as dose/ar~a, were 37.0 liters/hr [0.48 liter/(kg x hr)] for subject 1 and 41.1 liters/hr 
[0.44 liter/(kg x hr)] for subject 2. These high clearances suggested that diphenhydramine was 
subject to a first-pass effect. 
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solution curve was considerably less than the corresponding area following 
intravenous administration. The data also revealed that for one subject, 
but not the others, absorption of diphenhydramine from the commercial 
capsule was somewhat less than when the drug was administered orally in 
solution, 
Cumulative amount of unchanged diphenhydramine excreted in the 
urine following the two oral treatments was about 1% of the administered 
dose in both subjects, while that for intravenous infusion was about 2 ~,, 
for subject 1 and 3 ~o for subject 2. These low values excluded use of urinary 
excretion data as reliable measures of absorption efficiency. 
Data Analysis 
The polyexponential equations obtained by use of the program 
AUTOAN are given in Table III. The post-intravenous-infusion data for 
both subjects were described by a biexponential equation. Three of the four 
sets of oral data were described by a four-term exponential equation, while 
the fourth set was described by a five-term polyexponential equation. 
Although several models could be envisioned which might be appropriate, 
there is insufficient information in these data to make a judicious choice. 
Retrospectively, a more intensive plasma sampling scheme both immediately 
following cessation of the intravenous infusion and beyond the 24-hr time 
period would be necessary to permit choice of the most appropriate pharma- 
cokinetic model. 
The areas estimated by the two different methods are summarized in 




The extent of the first-pass effect on drug bioavailability may be deter- 
mined by equation 1 : 
0 = (d~ S~ Coral dt (1) 
(dose)oralf~ ~ Ci.v. dt 
where 0 represents the fraction of the drug which is administered by the oral 
route that reaches the general circulation. Rowland (7) has shown that for 
drugs exhibiting dose-independent kinetics the bioavailability of an oral 
dose of drug following its first-pass through the liver may be estimated by use 
of equation 2 : 
fm(dose)i.v. 
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Table IV. Summary of Estimated Areas 
Estimated area 0 to oc (ng/ml x hr) 
From integration of the 
Subject Treatment From trapezoidal r u l e "  AUTOAN equation b 
Intravenous infusion 1181 1046 c 
Solution, oral 579.2 617.2 
Capsule, oral 468.3 516.1 
Intravenous infusion 1062 1036 ~ 
Solution, oral 557,3 568.0 
Capsule, oral 530.6 581.7 
"Area = fg4C dt + C2jfi,  where the integral was estimated by trapezoidal rule, C24 is the 
observed plasma concentration at 24 hr, and fl = (In C12 - In C24)/12 where the Cx2 and C24 
are observed plasma concentrations at 12 and 24 hr, respectively, following intravenous in- 
fusion. 
~Area obtained by integrating the polyexponential equation in Table II1. 
"The area obtained by trapezoidal rule in the interval 0 to 1 hr was added to the area obtained 
by integrating the polyexponential equation given in Table Ill between limits of 1 hr to re. 
where f~ represents the fraction of the dose which is metabolized in the 
liver, I?sL is the liver b lood  flow rate, and 2 is the ratio of  the concentra t ion 
of drug in b lood to the concentra t ion of drug in plasma. Rowland (7) indicated 
that  when the value of 0 obtained from equat ion 1 is less than that  obtained 
from equat ion 2 then either absorpt ion is incomplete or metabol ism occurs 
in the gut or during passage of the drug across the gut wall. Alternatively, 
he indicated that  when the value of  0 obtained with equat ion 1 is greater than 
that obtained with equat ion 2 then the concentra t ion of  drug in the hepatic 
portal  vein following oral adminis t rat ion may be sufficiently high to saturate 
the metabolic  enzymes. 
The values of 0 calculated with equat ions 1 and 2 are given in Table V. 
The average value of 0.54 f rom equat ion 1 is only slightly greater than the 
value of  0.49 from equat ion 2 for subject 1, The average value of  0.51 from 
equat ion 1 is essentially the same as the average value of  0.50 from equat ion 
2 for subject 2. Interestingly, as pointed out  by one of  the reviewers, a recti- 
linear plot of the plasma concentra t ion data  for subject 2 suggests a possible 
linearity for bo th  the "dur ing  infusion" data  and the postinfusion data from 
1 to 4 hr. Yet for this subject the 0 values obtained with equat ions 1 and 2 
agree mos t  closely. Also, other tests for saturat ion kinetics failed to support  
a saturat ion phenomenon.  
The value off, ,  required for use of  equat ion 2 was obtained by means of 
equation 3 : 
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where fe is the fraction of the dose of drug which is excreted unchanged 
in the urine. These values, in percentage units, are given in Table II. The 
values in Table II, divided by 100, average 0.03 and 0.02 for subjects 1 and 2, 
respectively. The value of 2 was measured experimentally and found to 
average 0.82 for both subjects and to be independent of concentration. 
Efficiency of Absorption 
The bioavailability of diphenhydramine hydrochloride from Benadryl 
Kapseals relative to a solution of the drug given orally may be determined 
with equation 4: 
F = (dose)sol.. j.~o Coap 'd t  (4) 
(dose)cap ' f~  Csoln ' at 
Values of F calculated by means of equation 4 are given in Table V. The 
average values indicate that absorption from the capsule was only 83 
relative to the solution in subject 1 but that absorption was complete in 
subject 2. 
Plasma Protein Binding 
Table VI gives the percent unbound diphenhydramine at two concen- 
trations. Since the unbound fraction appeared to be independent of concentra- 
tion, a direct comparison of total plasma concentration (bound plus unbound) 
to assess bioavailability was justified. Also given in Table VI are the experi- 
mentally determined values of 2. As indicated above, these averaged 0.82 
for both subjects. 
Correlation of Somnolescence with Plasma Concentration 
Both subjects went to sleep shortly after the 1-hr intravenous infusion 
ceased, but were only drowsy following the oral treatments. From the data 
in Table II, one can calculate that the ratio of the peak plasma concentration 
of diphenhydramine following intravenous administration to that following 
oral administration of the drug in solution was 3.7 for subject 1 and 2.8 
Table V1. Diphenhydramine Plasma Binding and Blood/Plasma 
Distribution in Two Subjects 
Percent u n b o u n d  Blood/plasma 
Subject 113 ng/ml 1130 ng/ml 113 ng/ml 904 ng/ml 
1 1.5 1.3 0.83 0.82 
2 1.8 1.7 0.81 0.83 
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for subject 2. These results suggest that when the plasma concentration of 
diphenhydramine exceeds about 70 ng/ml sleep may occur. 
Elimination Half-Life 
Data collected failed to delineate useful elimination half-lives of di- 
phenhydramine in man. Apparent elimination half-lives are summarized 
in Table VII. These were calculated (a) from the observed plasma concentra- 
tions at 12 and 24 hr and (b) by dividing the smallest rate constant of the 
polyexponential equations (given in Table III) into the natural logarithm of 
2. The average of the eight half-lives obtained from the oral data is 15 hr, 
which agrees reasonably well with the value of 18 hr reported by Glazko 
et al. (3). However, comparison with the values obtained from the two sets 
of intravenous infusion data indicates that these values derived from oral 
data are overestimates of the " t rue"  elimination half-life, and probably 
indicate prolonged absorption of diphenhydramine following oral ad- 
ministration. It should also be noted from Table VII that the half-lives 
estimated from the smallest rate constants of the polyexponential equations 
fitted to the intravenous infusion data are smaller than those derived from the 
12- and 24-hr plasma concentrations for both subjects. This suggests that 
the log linear phase did not begin until beyond 12 hr. Thus this analysis of 
admittedly inadequate data suggests that in these two subjects the " t rue"  
elimination half-life of diphenhydramine was probably in the 4- to 7-hr 
ranges These data also suggest that estimation of elimination half-lives of 
diphenhydramine following either oral or intravenous administration 
requires measurement of plasma concentrations lower than 5 ng/ml and 
beyond 24 hr after dosing. 
Table VII. Apparent Elimination Half-Lives 
Apparent elimination half-life (hr) 
From 12- and 24-hr 
Subject Treatment plasma levels 
From smallest rate constant 
of polyexponential equations 
Intravenous infusion 7.59 4.17 
Solution, oral 15.0 12.6 
Capsule, oral 14.1 14.1 
Intravenous infusion 10.4 6.96 
Solution, oral 13.3 13.4 
Capsule, oral 21.2 16.0 
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CONCLUSIONS 
Diphenhydramine exhibits a large first-pass effecL with about 50~  
metabolism occurring before the drug reaches the general circulation 
following oral administration. The drug administered in solution orally is 
apparently fully available to the hepatoportal system. When administered 
in capsule form orally, the drug was completely absorbed in one subject and 
about 83 % absorbed in the other subject. Diphenhydramine is almost 
entirely biotransformed since less than 4 ~o of the dose was excreted un- 
changed ifl the urine. Future pharmacokinetic investigations with this drug 
will require more intensive and more prolonged sampling than used in this 
pilot study and an assay method sensitive to at least 1 ng/ml of piasma. 
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